ABSTRACT
Background In recent years, self-expanding technology to treat pulmonary regurgitation in the native RVOT became FDA approved in the U.S. and is now routinely used. The current practice for selection of patients who are candidates for these devices includes screening for “anatomic fit”, performed by each of the manufacturing companies. Our study aims to validate the use of virtual reality as a tool for local physician-led screening of patients.
Methods This retrospective study from Children’s Hospital Colorado included patients who underwent pulmonary valve replacement and had screening for a Harmony TPV or Alterra Pre Stent performed between September 2020 and January 2022. The data from the commercial companies dedicated analysis for self-expanding TPVR evaluation with perimeter analysis was collected. Virtual Reality simulation was performed blinded by two congenital interventional cardiologists using Elucis virtual reality software and an Oculus Quest 2 headset.
Results Among the 27 evaluated cases, the use of a self-expandable valve was recommended by companies dedicated analysis in 23 cases (85.2%), by VR assessment in 26 cases (96.3) and finally implanted in 25 cases (92.6%). Regarding the level of agreement, both modalities (Manufacturer and VR) were good at screening in patients who received a self-expanding valve (100% vs. 96.1%). When it came to screening the patients out, VR presented good capacity to accurately classify non-suitable patients (50% vs. 100%).
Conclusion Our institutional experience with virtual reality TPVR planning, accurately predicted clinical outcomes. This paves the way for routine use of VR in patient selection for self-expanding valve technologies.
Competing Interest Statement
Dr Gareth Morgan and Dr Jenny Zablah are consultants for Edwards Lifescience and for Medtronic.
Funding Statement
Project K: Legacy Grant from the World's Children's Initiative (WCI). In memory of Dr Kanishka Ratnayaka.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Colorado COMIRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data is available per request
